Kinnate Biopharma Inc.

NasdaqGS:KNTE Stock Report

Mkt Cap: US$291.5m

Kinnate Biopharma Future Growth

How is Kinnate Biopharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


0.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:KNTE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202524-194-169-2094
12/31/2024N/A-184-144-1725
12/31/2023N/A-150-121-1387
9/30/2022N/A-111-91-88N/A
6/30/2022N/A-105-88-85N/A
3/31/2022N/A-99-81-79N/A
12/31/2021N/A-90-72-71N/A
9/30/2021N/A-77-62-62N/A
6/30/2021N/A-63-53-53N/A
3/31/2021N/A-49-41-41N/A
12/31/2020N/A-36-30-30N/A
9/30/2020N/A-26-20-20N/A
12/31/2019N/A-10-11-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KNTE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KNTE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KNTE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KNTE is forecast to have no revenue next year.

High Growth Revenue: KNTE is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KNTE's Return on Equity is forecast to be high in 3 years time


Discover growth companies